A specific subtype of non\small\cell lung cancer (NSCLC) characterized with an fusion gene, which pushes constitutive oncogenic activation of anaplastic lymphoma kinase (ALK), shows a good clinical response to ALK inhibitors. an alanine in these two cell lines reduced the phosphorylation levels of AKT, one of the downstream oncogenic molecules in the EML4\ALK pathway, and… Continue reading A specific subtype of non\small\cell lung cancer (NSCLC) characterized with an